Paris Match Article We are excited to announce that the widely read French public magazine Paris-Match has featured an interview with Professor Guy Vallancien, head of the urology department at the Institut [of] Mutualiste Montsouris Paris. Professor Vallancien is the leading pioneer of robotic

Launches "@-REGISTRY" Database in the United Kingdom

ENLIGHT Newsletter We are excited that EDAP continues to make substantial progress with our U.S. clinical ENLIGHT trial. In the attached newsletter, please find a message from Cary Robertson, MD, the trial's Primary Investigator and John Rewcastle, PhD, EDAP's Medical Director, outlining the

The French Association of Urology Defines the Indications for HIFU as Standard of Care for Prostate Cancer

First Quarter 2008 Highlights: Total HIFU revenue of EUR 2.2 million, up 39% year-over-year Gross margin increased to 44.1% compared to 43.1% in the first quarter of 2007 Continued progress in U.S. ENLIGHT clinical study driven by IRB approval of 11 premier Ablatherm and 8 Cryotherapy sites 25% ENLIGHT enrollment growth in past six weeks

EDAP Adds Premiere M.D. Anderson Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, May 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that The University of Texas M.D.

EDAP Announces Webcast and Conference Call of First Quarter 2008 Results LYON, France, May 5, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2008 earnings announcement, which will take place on

EDAP Adds High Volume Cryotherapy Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, April 22, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Atlantic Urology in Daytona Beach, Florida has received Institutional

EDAP Adds World Renowned Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, April 10, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has received Institutional Review Board (IRB) approval for Memorial

Joint Cooperation With Epitarget AS and INSERM to Improve Delivery of Cancer Drugs With HIFU